	US 11,999,766 B2
	Modified S1 subunit of the coronavirus spike protein
Annika Kraemer-Kuehl, Seesen (DE); Thomas Min Stephan, Hannover (DE); and Hans-Christian Philipp, Hemmingen (DE)
Assigned to Boehringer Ingelheim Vetmedia GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein (DE)
Filed on Nov. 28, 2022, as Appl. No. 18/059,171.
Application 18/059,171 is a continuation of application No. 16/867,650, filed on May 6, 2020, granted, now 11,512,115.
Claims priority of application No. 19173821 (EP), filed on May 10, 2019; and application No. 19212627 (EP), filed on Nov. 29, 2019.
Prior Publication US 2023/0340028 A1, Oct. 26, 2023
Int. Cl. A61K 39/215 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/85 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/215 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20023 (2013.01); C12N 2800/10 (2013.01)]

18 Claims

1. A method for the production or manufacture of an avian coronavirus having extended cell or tissue tropism comprising mutating amino acid position 267 of an avian coronavirus spike protein or fragment of an avian coronavirus having restricted cell or tissue tropism to Cysteine, wherein the amino acid sequence of SEQ ID NO:1 is used for determining the position numbering in the spike protein, and wherein the mutation at amino acid position 267 to Cysteine leads to extended cell or tissue tropism of the avian coronavirus.